

Advanced Breast Cancer (Partial update) GC5 – minutes

Advanced breast cancer: diagnosis and management (Partial update)

Date: 05/09/2025

Location: Virtual

Minutes: FINAL

| Committee members present: | | |
|-----------------------------------|-----------------------------|--------------------------------------|
| Adam Firth | Chair | Present for notes 1 - 11 |
| Ramsey Cutress | Breast surgeon | Present for notes 1 - 11 |
| Mark Davies | Medical oncologist | Present for notes 1 - 11 |
| Milly Finch | Pharmacist Committee member | Present for notes 1 - 11 |
| Karen Lockwood | Lay member | Present for notes 1 - 11 |
| Simon Lowes | Radiologist | Present for notes 1 - 11 |
| Madeleine Meynell | Lay member | Present until partway through item 8 |
| Mitesh Naik | Radiologist | Present for notes 1 - 11 |
| Tim Robinson | Medical oncologist | Present until partway through item 7 |
| Clare Sacco | Lay member | Present for notes 1 - 11 |
| Elinor Sawyer | Clinical oncologist | Present for notes 1 - 11 |

| In attendance: | | |
|-----------------------|----------------------------------|--|
| Adefisayo Abba-Abba | Technical Analyst | Present for notes 1 - 11 |
| Victoria Carter | Implementation Support Manager | Present for notes 1 - 11 |
| Olivia Crane | Senior Technical Analyst | Present for notes 1 - 11 |
| Gareth Haman | Senior Guidance Content Designer | Present for notes 1 - 11 |
| Marie Harrisingh | Topic Lead | Present for notes 1 - 11 |
| James Hawkins | Health Economics Adviser | Present for notes 1 - 11 |
| Tzujung Lai | Health Economist | Present for notes 1 - 11 |
| Yolanda Martinez | Technical Analyst | Present for notes 1 - 11 |
| Adam O'Keefe | Project Manager | Present for notes 1 - 11 |
| Katherine Saxby | Pharmacist Clinical Adviser | Present for item 1 and then from partway through item 8 - 11 |

| NICE observers: | |
|------------------------|-------------------|
| Laura Berg | Technical Analyst |

Advanced Breast Cancer (Partial update) GC5 – minutes

| | |
|----------------------|-------------------|
| Matthew Bosworth | Technical Analyst |
| Charlotte Fairclough | Technical Analyst |

Apologies:

| | |
|------------------|-------------------------------|
| Ben Thwaites | Pharmacist |
| Caroline Tweedie | Clinical Nurse Specialist |
| Andrea Heath | Senior Information Specialist |

1. Welcome, introductions and apologies

The Chair welcomed the committee members and NICE attendees to the fifth committee meeting for the partial update to the NICE Advanced breast cancer: diagnosis and management guideline.

The Chair informed the Committee that apologies had been received. These are noted above.

2. Declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was Advanced breast cancer.

The Chair asked committee members to verbally declare any new interests, the following new interests were declared:

| Name | Declaration | Date DOI arose | Action |
|-------------|---|----------------|---|
| Milly Finch | Roche sponsored attendance, travel and accommodation at the BOPA 2025 symposium | Oct 2025 | Non-specific. Declare and participate. |
| Simon Lowes | Member of the Royal College of Radiologists Professional Practice Board | Aug 2025 | Non-specific. Declare and participate. |

The Chair and a senior member of the Developer's team noted that neither this interest nor any previously declared interests would prevent attendees from fully participating in the meeting.

| |
|---|
| 3. Minutes of the previous meeting |
| The minutes of the previous meeting were ratified as an accurate record. |
| 4. Visual summaries |
| The Chair introduced Katherine Saxby, Pharmacist Clinical Adviser who discussed with the committee the production of visual summaries to support the guideline. |
| 5-6. Review Question 2: What is the clinical and cost effectiveness of FDG PET-CT and CT with or without bone scintigraphy for the detection of distant metastases in people with suspected advanced breast cancer and does this use of FDG PET-CT improve outcomes? |
| The Chair introduced Adefisayo Abba-Abba, Technical Analyst, who presented to the committee the clinical evidence identified to inform this review question. The Chair then introduced James Hawkins, Health Economics Adviser who presented the cost-effectiveness evidence identified. The committee discussed the evidence, and equalities and health inequalities considerations but agreed to wait until the results of the economic modelling being produced are presented at the next meeting, before drafting recommendations in this area. |
| 7. Review Question 3: What is the clinical and cost effectiveness of FDG PET-CT compared to CT with or without bone scintigraphy for monitoring response to treatment and for detecting disease progression in people with advanced breast cancer? |
| The Chair introduced Yolanda Marinez, Technical Analyst, who explained that there had been no clinical evidence identified to inform this review question. James Hawkins then presented the cost-effectiveness evidence identified. The committee discussed the evidence but agreed to wait until the results of the economic modelling being produced are presented at the next meeting, before drafting recommendations in this area. |
| 8. Health economics |
| The Chair reintroduced James Hawkins and Tzujung Lai, Health Economist, who updated on and discussed with the committee, the health economic modelling to being developed to inform the guideline update. |
| 9. Revisit Review Question 1.1: Platinum-containing chemotherapies recommendations |
| The Chair introduced Marie Harrisingh, Topic Lead, who revisited and updated the recommendations drafted for Review Question 1.1: Platinum-containing chemotherapies with the committee |

Advanced Breast Cancer (Partial update) GC5 – minutes

10. Refreshing recommendations

This item was deferred to the next meeting due to time constraints.

11. AOB, Summary and next steps

The Chair outlined next steps following the meeting, thanked the committee for their contributions, summarised the main actions from the day and asked for items of any other business.

Olivia Crane, Senior Technical Analyst, revisited and clarified a discussion point from the discussion on Review Question 2 with the committee

The Chair then brought the meeting to a close.

Date of next meeting: 17/10/2025

Location of next meeting: Virtual